157 results about "Bacterial host" patented technology

Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for pesticidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated pesticidal nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:2, 4, 6, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37 or 61, the nucleotide sequence set forth in SEQ ID NO:1, 3, 5, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, or 60, or the nucleotide sequence deposited in a bacterial host as Accession No. NRRL B-30961, B-30955, B-30956, B-30957, B-30958, B-30942, B-30939, B-30941, B-50047, B-30959, B-30960, B-30943, or B-50048, as well as variants and fragments thereof.

The invention relates to unglycosylated folded C-terminal fragments of a multidomain serine protease of the complement cascade obtainable by expression in a bacterial host, wherein said serine protease is capable of binding a recognition molecule of the complement cascade, e.g. C1 or MBL. The invention also relates to methods and bacterial expression vectors for the preparation of said fragments, uses of said fragments for raising antibodies and screening substrates or inhibitors of said serine proteases and uses of the fragments in research and treatment of complement related disorders. The invention also relates to assay methods for assessing MASP-1 and MASP-2 levels in a sample of biological origin.The invention provides for research tools, assays and diagnostic kits useful in complement research and research and diagnosis of complement related disorders.

The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.

Long rod shaped M13 viruses were used to fabricate one dimensional (1D) micro- and nanosized diameter fibers by mimic the spinning process of the silk spider. Liquid crystalline virus suspensions were extruded through the micrometer diameter capillary tubes in cross-linking solution (glutaraldehyde). Resulting fibers were tens of micrometers in diameter depending on the inner diameter of the capillary tip. AFM image verified that molecular long axis of the virus fibers were parallel to the fiber long axis. Although aqueous M13 virus suspension could not be spun by electrospinning, M13 viruses suspended in 1,1,1,3,3,3-hexafluoro-2-propanol were spun into fibers. After blending with highly water soluble polymer, polyvinyl 2-pyrolidone (PVP), M13 viruses was spun into continuous uniform virus blended PVP (virus-PVP) fibers. Resulting virus-PVP electrospun fibers showed intact infecting ability to bacterial hosts after suspending in the buffer solution.

The present invention relates to the field of recombinant toxin protein production in bacterial hosts. In particular, the present invention relates to production processes for obtaining high levels of a recombinant CRM197, Diphtheria Toxin, Pertussis Toxin, Tetanus Toxoid Fragment C, Cholera Toxin B, Cholera holotoxin, and Pseudomonas Exotoxin A, from a bacterial host.

Methanotrophic bacterial strains are provided that have been optimized for the production of carotenoid compounds through the down-regulation of one or more of the crtN1, aid, crtN2 and crtN3 genes of the carotenoid biosynthetic pathway. The resulting strains lack pigmented C30 carotenoid compounds, and show an increase in the production of C40 carotenoids. The use of the optimized host strains for the production of the C40 carotenoids canthaxanthin and astaxanthin is also described.

The invention relates to the field of microbes and provides a novel salmonella phage and a composition, a preparation method and application thereof. The novelsalmonella phage is Myoviridaesp. BP-66 with the preservation numberCCTCC NO: M2015146,Myoviridaesp. BP-63 with preservation number CCTCC NO: M2015145, or Chilikevirussp. BP-12 with the preservation number CCTCCNO: M2015141. The novel phage is a strict virulent phage, has high toxicity to host bacteria, has a wider host range and still has high toxicity to the host bacteria at low concentration. The DNA of the phage cannot encode protein possibly causing potential health risks. The novel phage stably survives in a culture solution at room temperature and survive for more than 6 months at the temperature below 4 DEG C. In addition, the phage can be proliferated on pathogenic bacterial hosts, and large-scale industrial production can be achieved. The salmonella phage can provide excellent strain resources for application of phage therapy.

The invention discloses a microbial cell sensor for detecting toluene organic pollutants and a detection method thereof, and relates to a microbial cell sensor for detecting toluene organic pollutants, which is constructed by using a regulatory sequence of pseudomonas putida degradation genes and a plasmid sequence of regulatory protein genes and commercial report genes, and a detection method thereof. The bacterial host is Escherichia coli, and is used for detecting toluene organic matters. The lowest detection concentration on the toluene is 40 micromoles per liter, and the highest detection concentration on the toluene is 1,000 micromoles per liter.

The present invention features therapeutic bacteriophage deficient in the lysin protein (“Lys minus” phage). Lys minus bacteriophage are incapable of facilitating efficient lysis of the bacterial host since the enzymatic activity of the lysin of the phage is needed for breaking down the peptidoglycan layer of the bacterial cell wall. Lys minus bacteriophage retain activity in invasion of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. Therefore, the therapeutic Lys minus phage stops the spread of infection by the bacterial pathogen without lysis of the bacterium. This approach is attractive as it also prevents the release of the phage progeny, thus reducing or eliminating the potential for generation of immune responses against the phage. The incapacitated bacterial pathogen is then removed by the normal defense systems such as phagocytes and macrophages.

The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.

The invention relates to unglycosylated folded C-terminal fragments of a multidomain serine protease of the complement cascade obtainable by expression in a bacterial host, wherein said serine protease is capable of binding a recognition molecule of the complement cascade, e.g. C1 or MBL. The invention also relates to methods and bacterial expression vectors for the preparation of said fragments, uses of said fragments for raising antibodies and screening substrates or inhibitors of said serine proteases and uses of the fragments in research and treatment of complement related disorders. The invention also relates to assay methods for assessing MASP-1 and MASP-2 levels in a sample of biological origin.The invention provides for research tools, assays and diagnostic kits useful in complement research and research and diagnosis of complement related disorders.

The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.